1. Cell Cycle/DNA Damage
  2. Topoisomerase
  3. Karenitecin

Karenitecin (Synonyms: Cositecan; BNP 1350)

製品番号: HY-14812 純度: 98.27%

Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.


Karenitecin 構造式

Karenitecin 構造式

CAS 番号 : 203923-89-1

容量 価格(税別) 在庫状況 数量
5 mg USD 510 在庫あり
Estimated Time of Arrival: December 31
10 mg USD 780 在庫あり
Estimated Time of Arrival: December 31
25 mg USD 1700 在庫あり
Estimated Time of Arrival: December 31
50 mg USD 2500 在庫あり
Estimated Time of Arrival: December 31
100 mg USD 3750 在庫あり
Estimated Time of Arrival: December 31
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください


Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

Topoisomerase アイソフォーム固有の製品をすべて表示:

  • 生物活性

  • プロトコル

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー


Karenitecin (Cositecan) is a topoisomerase I inhibitor, with potent anti-cancer activity.

IC50 & Target

Topoisomerase I



Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. Karenitecin inhibits cell growth of A253 cells with IC10, IC50, and IC90 values of 0.01, 0.07, and 0.7 μM after 2 h treatment. Karenitecin induces DNA damage (0.01, 0.07, and 0.7 μM), and increases cyclin E and cdk2 protein expression in A253 cells (0.07, and 0.7 μM). Karenitecin markedly enhances the cyclin B/cdc2-associated kinase activity at low concentration, but slightly suppresses this kinase activity at higher concentration[1]. Karenitecin inhibits several human colon cancer cell lines such as COLO205, COLO320, LS174T, SW1398 and WiDr cells, with IC50s of 2.4 nM, 1.5 nM, 1.6 nM, 2.9 nM, and 3.2 nM, respectively[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Karenitecin shows maximum growth inhibition of 61% on COLO320 cells and 54% on COLO205 colon cancer cells via i.p. administration of 1 mg/kg in mice. Karenitecin (1.0 mg/kg daily × 5 i.p.) significantly suppresses growth inhibition both in the parental Pgp-negative xenografts and in the Pgp-positive xenografts[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.





CAS 番号

O=C1[[email protected]](O)(CC)C2=C(CO1)C(N3CC4=C(CC[Si](C)(C)C)C5=CC=CC=C5N=C4C3=C2)=O


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度

DMSO : 3.03 mg/mL (6.75 mM; ultrasonic and warming and heat to 60°C)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2292 mL 11.1460 mL 22.2921 mL
5 mM 0.4458 mL 2.2292 mL 4.4584 mL
10 mM --- --- ---
*Please refer to the solubility information to select the appropriate solvent.

sup>[1]Cell growth inhibition is determined using the total protein SRB assay as described elsewhere. Briefly, 600 cells/well are seeded onto 96-well plates. After 24 h, exponentially growing A253 cells are treated with Karenitecin, which is diluted in culture medium, for 2 h. At four doubling times after drug exposure, the cells are fixed with 10% trichloroacetic acid and further processed according to the published SRB procedure. The optical density is measured at 570 nm. Antiproliferative activities are expressed as drug concentrations that induce growth inhibition of 50 or 90% compared with growth of untreated controls (IC50 and IC90 values)[1].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


The human tumor xenografts grown in nude mice are measured twice a week in 3 dimensions with vernier calipers. The volume is calculated by the equation length × width × thickness × 0.5, and expressed in mm3. At the start of treatment (designated as day 0), groups of 5 to 6 tumor-bearing mice are formed to provide a mean tumor volume of approximately 150 mm3 in each group. Doses of Karenitecin and CPT-11 for the daily × 5 schedule are administered according to the maximum tolerated dose (MTD) for tumor-bearing mice. This maximum tolerated dose is based on the occurrence of a mean weight loss of approximately 10% of the initial weight within the first 2 weeks after the start of the treatment. Recovery of the weight loss should be completed on day 14; consequently, mice are weighed on weekdays for 2 weeks and, thereafter, twice a week. The MTD is assessed in groups of 3 non-tumor-bearing nude mice per dose level[2].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • モル濃度カルキュレーター

  • 希釈カルキュレーター

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2



Your information is safe with us. * Required Fields.




お名前 *


PC 用メールアドレス *

電話番号 *


勤務先/学校名 *

Department *


カスタマ需要量 *

国会或いは地域 *





Inquiry Information

MCE 日本正規代理店: